Tissue transglutaminase in tumour progression: Friend or foe?

P. Kotsakis, Martin Griffin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Basic biological processes in which tissue transglutaminase (TG2, tTG) is thought to be important including apoptosis, cell adhesion and migration, ECM homeostasis and angiogenesis are key stages in the multistage tumour progression cascade. Studies undertaken with primary tumours and experimental models suggest that TG2 expression and activity in the tumour body and surrounding matrix generally decreases with tumour progression, favouring matrix destabilisation, but supporting angiogenesis and tumour invasion. In contrast, in the secondary metastatic tumour TG2 is often highly expressed whereby its potential roles in cell survival both at the intra- and extracellular level become important. In the following review the underlying molecular basis for the selection of these different phenotypes in tumour types and the anomaly for the requirement of TG2 is discussed in relation to the complex events of tumour progression. © 2007 Springer-Verlag.

Original languageEnglish
Pages (from-to)373-384
Number of pages12
JournalAmino Acids
Issue number2
Publication statusPublished - Aug 2007


  • angiogenesis
  • enzyme
  • extracellular matrix
  • tissue transglutaminase
  • tumour growth


Dive into the research topics of 'Tissue transglutaminase in tumour progression: Friend or foe?'. Together they form a unique fingerprint.

Cite this